Filing summary
Entity and period: The supplied filing is NanoAntibiotics, Inc.’s unaudited Form 10-Q for the three months ended September 30, 2014, not a BioVie Inc. filing. September 30 appears to be the company’s fiscal first quarter; the filing compares results with the three months ended September 30, 2013.
Business context
NanoAntibiotics describes itself as an early-stage biotechnology company developing antibiotic candidates, including nano efflux pump inhibitors and a nanoantibiotic. It had no products for sale, no revenue, and reported that its candidates had been studied only in cell-based assays, not in animals. The company was pursuing outside technology licensing and planned to contract research and development to third parties.
Financial performance and position
| Metric | Three months ended September 30, 2014 | Prior-year comparable period |
|---|---|---|
| Revenue | $0 | $0 |
| Operating expenses | $58,890 | $53,583 |
| Operating loss | $58,890 | $53,583 |
| Net loss | $58,776 | $53,493 |
| Operating cash used | $14,717 | $59,848 |
| Cash at period end | $318,147 | $445,848 |
Gross margin was $0 because there were no sales; a percentage margin is not meaningful. Research and development expense declined to $3,400 from $11,420, while professional fees were $12,244 and selling, general and administrative expense was $2,421, versus zero in the prior-year quarter for each. Cash flow benefited from increases in accrued payroll ($40,369) and accounts payable ($1,800), so operating cash use was substantially below net loss.
At September 30, 2014, total assets were $318,147, all cash. Current liabilities were $203,644, comprising accrued payroll of $201,844 and accounts payable of $1,800; the filing reports no debt or interest expense. Stockholders’ equity was $114,503. Cash had declined by $14,717 from June 30, 2014. The company had 87,210,000 common shares outstanding and 5,000,000 unexercised warrants exercisable at $0.50 per share.
Changes, outlook and risks
- Net loss increased by $5,283 year over year, while total operating expenses rose by $5,307. The filing attributes the expense mix partly to new professional fees and general and administrative costs, alongside lower R&D spending.
- Management estimated next-12-month spending of $575,000 for R&D, $100,000 for corporate overhead, $100,000 for licensing and capital costs, and $180,000 for officers and staffing. It said approximately $600,000 of additional net financing was needed to meet its budget and that available funds were insufficient for planned activities for the next 12 months.
- The filing also states that existing cash was expected to meet operating and capital requirements until June 30, 2015. Management warned that the company had no committed financing and that failure to raise funds could force it to delay or scale back development, seek licensing or strategic alternatives, or cease operations. The filing states that these conditions raise substantial doubt about the company’s ability to continue as a going concern.
- Management discussed possible licensing of nanotechnology and estimated that a technology under review could require an additional $500,000 in development costs. These plans and estimates were subject to change and dependent on financing.
- The company disclosed that its disclosure controls and procedures were not effective as of September 30, 2014. It reported no material change in internal control over financial reporting during the quarter.
- The company reported a five-year office lease beginning January 1, 2014, with monthly payments of $357 and total scheduled payments of $21,420. It reported no material legal proceedings and no material off-balance-sheet arrangements.
Important facts for investors to verify
- Confirm the intended issuer: the provided filing names NanoAntibiotics, Inc., whereas the request identifies BioVie Inc.
- Reconcile the stated June 30, 2015 cash runway with management’s estimate that approximately $600,000 of additional financing was needed for planned 12-month spending.
- Assess the availability and terms of financing, licensing, or partnership arrangements; none is described as committed in the filing.
- Verify development progress, intellectual-property and licensing status, and the substantial preclinical, regulatory, and commercial risks of candidates not yet tested in animals.
- Review remediation of ineffective disclosure controls and monitor accrued payroll and other obligations relative to available cash.